Abstract. To clarify the matrix metalloproteinase (MMP)9 inhibitory effect of an angiotensin converting enzyme (ACE) inhibitor in vivo, we evaluated the effect of an ACE inhibitor against elastaseinduced abdominal aortic aneurysm (AAA) progression in mice. Molecular models showed that imidapril bound directly to the mouse MMP9 active center. An active form of imidapril, imidaprilat, dosedependently inhibited MMP9 activity in the extract from elastase induced AAA in wildtype mice. Imidapril (10 mg/kg per day) was administered to wildtype or angiotensin II type 1 (AT 1 ) receptor knockout mice. Blood pressure was significantly lower in AT 1 receptor-knockout mice than in wildtype mice, but imidapril did not affect blood pressure in AT 1 receptor-knockout mice. The aortic diameter was significantly expanded after elastase application, but the expansion was significantly lower in AT 1 receptor-knockout mice than in wildtype mice. In AT 1 receptor-knockout mice, the aortic expansion was further attenuated by imidapril. MMP9 activity in aorta was significantly augmented after elastase application. The MMP9 activity was significantly lower in AT 1 receptor-knockout mice than in wildtype mice, and it was further attenuated by imidapril. In conclusion, MMP9 inhibition by imidapril might contribute to the attenuation of AAA progression in AT 1 receptor-knockout mice.
Introduction
Abdominal aortic aneurysm (AAA) expansion is characterized by chronic inflammatory cell infiltration and extracellular matrix degradation (1) . The patho genesis of AAA may be related to hypertension (2) . Daugherty et al. (3) demonstrated that a 4weekinfusion of angiotensin II into apolipoprotein E-deficient mice induced AAA formation. However, noradrenaline raised the blood pressure in apolipoprotein E-deficient mice to the same degree as the angiotensin II infusion, but noradrenaline did not induce AAA development (4) . Moreover, hydralazine could not attenuate AAA forma tion in the angiotensin II-infused apolipoprotein Edeficient mice despite lowering blood pressure (5) . Thus, the augmentation of angiotensin II action rather than blood pressure may be important for inducing AAA development.
Angiotensin II is formed from angiotensin I by angio tensinconverting enzyme (ACE), and it shows vascular constriction via stimulation of angiotensin II type 1 (AT 1 ) receptors. On the other hand, angiotensin II also augments the production of reactive oxygen stress (ROS) via activation of NADPH oxidase in vascular tissues. Matrix metalloproteinase (MMP)9 plays an important role in the degradation of extracellular matrix in AAA (6) . MMP9 gene expression is induced by ROS, and angiotensin II-induced MMP9 gene expression may play an important role in the pathogenesis of AAA (7) . In fact, an MMP inhibitor attenuated angiotensin IIinduced AAA formation in apolipoprotein E-deficient mice (8) . However, various factors other than angio
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tensin II stimulation may also induce MMP9 gene expression (9) . Therefore, MMP9 inhibition in addition to angiotensin II inhibition may be a useful strategy for prevention of AAA development.
Both ACE and MMP9 are Zn 2+ dependent endo peptidases, and the ACE inhibitor captopril directly inhibits MMP9 activity in rat kidney extract (10) . Molecular models of complexes formed by the active center of MMP9 and ACE inhibitors have been con structed based on Xray structural analyses using the complexes formed by an active center of ACE and an ACE inhibitor in humans (11 -13) . In in vitro experi ments, ACE inhibitors could directly inhibit MMP9 activity in extracts from cardiovascular tissues in humans and hamsters (11 -14) . However, it has been unclear whether ACE inhibitors have a direct inhibitory effect on MMP9 activity in vivo.
The aim of the present study was to clarify the MMP9 inhibitory effect of an ACE inhibitor for the prevention of AAA development in vivo. Firstly, a molecular model of a complex formed by an active center of mouse MMP 9 and an ACE inhibitor was created. Second, the effect of the ACE inhibitor against elastaseinduced AAA development was evaluated in AT 1 receptor-knockout mice.
Materials and Methods

Molecular modeling of mouse MMP-9 and the imidaprilat complex
The molecular structure of mouse MMP9 was con structed from the Xray crystal structure of human ProMMP9 and the mouse MMP9 amino acid sequence, by using the homology modeling method implemented in an interactive molecular modeling package, MOE (Chemical Computing Group, Inc., Montreal, Canada) (15, 16) . The structure from Val 29 to Gly 444 of mouse MMP9 was built because of homology to the Xray structure of human ProMMP9, including the active domain, three fibronectin typeII domains, and a part of the precursor domain. This model structure was opti mized by energy minimization using MMFF94x force field and water molecules in a 6Å layer around the protein molecule (17) .
For modeling the active form of imidapril, the imi daprilat complex of the above model, the binding structure of imidaprilat to the Zn 2+ active center was constructed by referring to the ACE active center inhib ited by lisinopril (18) . Two interaction modes were modeled for the complex, as described in the Results section. Water molecules were regenerated around the complex, and optimization was performed by energy minimization under conditions of fixed metal ions. The energy cutoff distance was set at 10 Å, and the dielectric constant was distancedependent based on a value of 1.0 for the protein complex and 80.0 for the solvent. Then, 200picosecond (ps) molecular dynamics simula tions were performed on each model at 300 K using a 0.002ps time step, the MMFF94x force field, and the NVT method (19, 20) . Before these equilibrium itera tions, 1ps heating iterations were used to consider stable equilibration. The metal ions were all fixed. Finally, the most stable structure of each model during the later 100 ps simulations was optimized by energy minimization.
Drugs
Imidapril and imidaprilat were obtained from Mitsubishi Tanabe Pharma Co. (Osaka). A prodrug of ACE inhibi tor, imidapril, is metabolized in vivo to the active form imidaprilat by various esterases.
Animals
Male, 12weekold, global AT 1 receptor-knockout mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Male, 12weekold, wildtype C57 BL/6 mice were obtained from Japan SLC (Shizuoka). All mice were fed a normal diet and received water ad libitum. All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals at Osaka Medical College.
Elastase-induced AAA model
A mouse experimental model of AAA induced by application of elastase was modified from a previous report (21) . Under pentobarbital anesthesia (50 mg/kg, i.p.), the abdominal aorta from the infrarenal aorta to the bifurcation of the aorta was isolated, and the exposed abdominal aorta was circumferentially wrapped with gauze, onto which 200 units/mL of porcine pancreatic elastase (type I; SERVA Electrophoresis GmbH, Heidelberg, Germany) in saline were applied for 1 h.
Fourteen days after elastase application, the abdominal aorta was evaluated in wildtype and AT 1 receptorknockout mice. To investigate the effect of imidapril in wildtype and AT 1 receptor-knockout mice, each mouse was orally administered imidapril (10 mg/kg per day) or placebo (0.1% carboxymethyl cellulose), beginning 3 days before application of elastase (each group: n = 7). Wildtype and AT 1 receptor-knockout mice not given elastase were used as normal wildtype and normal AT 1 receptor-knockout mice (each group: n = 7).
Inhibitory effects of MMP-9 by imidaprilat
For the inhibitory effect of imidaprilat, which is an active compound of imidapril, against MMP9 activity, extract from elastaseinduced AAA was obtained 14 days after elastase application in wildtype mice. Using the extract, the activity was measured under each dose of imidaprilat from 1 mM to 1 mM using an MMP9 (mouse) activity assay kit (QuickZyme Biosciences, Leiden, The Netherlands).
Measurement of blood pressure
Systolic blood pressure (SBP) was determined in conscious mice using a computerized tailcuff method (BP98A; Softron, Tokyo). SBP was recorded 7 days before and 14 days after treatment with saline or elastase. The mean SBP was calculated based on 3 measurements per mouse.
Aortic diameter determined by ultrasound imaging
The diameter of the suprarenal aorta was measured using an echocardiograph (Nemio30; Toshiba, Tokyo) and a linear transducer (14.5 MHz), as described pre viously (22) . In brief, the aorta was longitudinally visual ized by scanning the abdomen with the transducer. The maximal luminal width of the aorta was measured before, immediately after, and 14 days after elastase application.
Preparation of aortic tissues
After anesthesia with sodium pentobarbital (50 mg/kg, i.p.), the abdominal aorta was removed 14 days after elastase treatment. For histological assessment, half of the tissues was fixed with Carnoy's fixative in 10% methanol overnight, and the remaining tissues were immediately frozen for enzymatic assessment at −80°C.
Histological assessment
The fixed aortic tissues were embedded in paraffin blocks and cut into 3mmthick slices. The extent of aortic dilatation was compared by examining the luminal area of sections taken at the abdominal aorta that were stained with Elastica von Gieson.
Scoring of elastic degradation
Elastic degradation in the aorta was scored blindly according to a modified classification of Zhou et al. (23): 0, no degradation; 1, less than 25% degradation; 2, 25% -50% degradation; 3, 50% -75% degradation; 4, greater than 75% degradation.
Enzyme activities
ACE and MMP9 activities in the aorta were measured as described previously (24) . In brief, the tissues were minced and homogenized in 20 mM TrisHCl buffer, pH 8.3, containing 5 mM Mg(CH 3 COO) 2 , 30 mM KCl, 250 mM sucrose, and 0.5% Nonidet P40. The supernatant was used for the measurement of ACE and MMP9 activities. ACE activity was measured by incubating the tissue extracts for 30 min at 37°C with 5 mM hippuryl-His-Leu in 10 mM phosphate buffer, pH 8.3, containing 600 mM NaCl (24) . The reaction was terminated by addition of 3% metaphosphoric acid, and then the mixture was centrifuged at 8,000 g for 5 min at 4°C. The supernatant was applied to a reversedphase column (4.6 mm i.d. × 250 mm, CAPCELL PAK C18 MG S5; Shiseido, Tokyo), which had been equilibrated with 10 mM KH 2 PO 4 and CH 3 OH (1:1, pH 3.0), and eluted with the same solution at a rate of 0.5 mL/min. Hippuric acid was detected by ultraviolet absorbance at 228 nm. One unit of ACE activity was defined as the amount of enzyme that cleaved 1 mmol hippuric acid/min.
MMP9 activity in the tissue extracts was detected using an MMP9 (mouse) activity assay kit (QuickZyme Biosciences).
The protein concentration was assayed using BCA Protein Assay Reagents (Pierce, Rockford, IL, USA), with bovine serum albumin as the standard.
Statistical analyses
Data are expressed as means ± S.E.M. Significant differences among the mean values of multiple groups were evaluated using 1way analysis of variance followed by Fisher's test. Values of P < 0.05 were considered significant.
Results
Interaction modes between imidaprilat and the mouse MMP-9 active site
The molecular model of mouse MMP9 was prepared by the homology modeling method from the human MMP9 precursor structure (15) . In this molecular model, the Cterminal hemopexin domain was not included because of its lack in the template structure; thus, the precursor domain, active domain, and three fibronectin typeII domains were included. This mouse precursor model was virtually activated by deletion of the precursor domain via the disconnection between Phe 108 and Gln 109 , in order to simulate the activation by chymase (25) . Because the active site of MMP9 reportedly has two hydrophobic sites (S1 and S1'), it was thought that the phenylethyl moiety of imidapril might interact with them. Two molecular structures that revealed these interaction modes were constructed based on Xray structures of the ACE-ACEinhibitor complex and MMP-MMPinhibitor complex, as follows: modeA, where the phenylethyl moiety of imidaprilat interacts with the MMP9 S1 side; and modeB, where that moiety interacts with the S1' side (18, 26 -28) . Molecular structures and interaction schemes related with these interaction modes are shown in Fig. 1 .
In modeA, as shown in Fig. 1 , but the terminal carboxyl group was positioned in the water phase.
In modeB, as shown in Fig. 1 (15, 28) . The imidazolidine ring and the terminal carboxyl group were placed in the same position as in modeA. The NH and central C = O groups were also fixed by hydrogen bonds to Ala 189 O and Leu 188 N, but this interaction seemed weaker than in modeA.
Inhibitory effects of imidaprilat on MMP-9
In the extract from AAA induced by elastase in AT 1 receptor-knockout mice, imidaprilat dosedependently inhibited MMP9 activity (Fig. 2) . The IC 50 value for the inhibition of mouse MMP9 activity was 6.8 mM (Fig. 2) . Threedimensional models for two interaction modes, modeA and modeB, are shown in panels (A) and (B) as stick models without hydrogen atoms. The Ca traces of the active domain and fibronectin domains are superimposed by a white and light blue tube, respectively. Imidaprilat is shown in green with the related residues of MMP9 being shown in white. Nitrogen, oxygen, and zinc atoms are colored blue, red, and purple. Each hydrogen bond between MMP 9 and imidaprilat is indicated by a green thin line, as is a chelate bond to zinc, and the related atoms are described by balls. Interaction schemes between the MMP9 active site and imidaprilat. Intermolecular interactions for modeA and modeB are shown in panels (C) and (D) with related amino acid residues. Hydrophobic interac tion, ring stacking, hydrogen bond, and chelate bond are depicted as orange curve, yellow wavy line, lightblue dash line, and bluelight wavy line. 
Effects of imidapril on the blood pressure in AT 1 receptorknockout mice
Before elastase application, SBP was significantly lower in AT 1 receptor-knockout mice than in wildtype mice (Fig. 3A) . Fourteen days after elastase application, SBP was unchanged in wildtype and AT 1 receptorknockout mice, and it was also significantly lower in AT 1 receptor-knockout mice than in wildtype mice (Fig. 3B) . On the other hand, imidapril showed a signifi cant hypotensive effect in wildtype mice (Fig. 3B) , but a further hypotensive effect of imidapril was not observed in AT 1 receptor-knockout mice (Fig. 3B) .
Effect of imidapril on aortic diameter by ultrasound imaging
Typical ultrasound images of aortas before and after elastase application in a wildtype mouse are shown (Fig. 4A) . Before elastase application, the maximum diameter of the abdominal aorta was not different among the groups (Fig. 4B) . Just after elastase application, the diameter was significantly expanded in all elastase applied groups in both wildtype and AT 1 receptorknockout mice, including the imidapriltreated groups, and there was no significant difference among these groups (Fig. 4B) . Fourteen days after elastase applica tion, the diameter was further expanded in wildtype mice (Fig. 4B ), but it was significantly attenuated in imidapriltreated wildtype mice and AT 1 receptorknockout mice. In elastaseapplied AT 1 receptorknockout mice, the diameter was significantly smaller in the imidapriltreated group than in the placebotreated group (Fig. 4B) .
Effect of imidapril on the luminal area in the aorta on histological analysis
Typical photographs of normal, elastaseapplied wild type mice and elastaseapplied AT 1 receptor-knockout mice treated with and without imidapril are shown (Fig. 5A) . The luminal area of the aorta was significantly greater in elastaseapplied wildtype mice than in normal wildtype mice, but it was significantly smaller in imidapriltreated and elastaseapplied wildtype mice than in elastaseapplied wildtype mice (Fig. 5B) . The luminal area was significantly smaller in elastaseapplied AT 1 receptor-knockout mice than in elastaseapplied wildtype mice, and it was further smaller in elastase applied AT 1 receptor-knockout mice treated with imi Fig. 3 . SBP in normal wildtype mice (N: Wildtype, n = 7), elastaseapplied wildtype mice (E: Wildtype, n = 7), imidapriltreated and elastaseapplied wildtype mice (E + I: Wildtype, n = 7), normal AT1 receptor-knockout mice (N: AT1KO, n = 7), elastaseapplied AT1 receptorknockout mice (E: AT1KO, n = 7) and imidapriltreated and elastaseapplied AT1 receptor-knockout mice (E + I: AT1KO, n = 7) 7 days before elastase application (A) and 14 days after elastase application (B). **P < 0.01 vs. elastase applied wildtype mice. Fig. 4 . Effect of imidapril on aortic diameter after elastase applica tion in wildtype AT1 receptor-knockout mice. Typical ultrasound images of aortas before and after elastase application in a wildtype mouse (A). The aortic diameter on ultrasound analysis in normal wild type mice (closed circles, n = 7), elastaseapplied wildtype mice (open circles, n = 7), imidapriltreated and elastaseapplied wildtype mice (open diamonds, n = 7), normal AT1 receptor-knockout mice (closed triangles, n = 7), elastaseapplied AT1 receptor-knockout mice (open triangles, n = 7), and imidapriltreated and elastaseapplied AT1 receptor-knockout mice (open squares, n = 7) 7 days before elastase application (Pre), just, and 14 days after elastase application (B). **P < 0.01 vs. elastaseapplied wildtype mice.
# P < 0.05 and ## P < 0.01 vs. elastaseapplied AT1 receptor-knockout mice.
dapril than in elastaseapplied AT 1 receptor-knockout mice (Fig. 5B) .
Effect of imidapril on the elastic degradation score
In wildtype mice, the elastic degradation score was significantly larger in the elastaseapplied group than in the normal group, but the score was significantly smaller in the imidapriltreated and elastaseapplied group than in the elastaseapplied group (Fig. 5C ). The elastic degradation score was also significantly greater in the elastaseapplied group than in the normal group in AT 1 receptor-knockout mice, but the score was signifi cantly reduced by treatment with imidapril (Fig. 5C ). The score was significantly lower in elastaseapplied AT 1 receptor-knockout mice than in elastaseapplied wildtype mice, (Fig. 5C ).
Effect of imidapril on MMP-9 and ACE activities in the aorta
MMP9 activity in the aorta was significantly higher in elastaseapplied wildtype mice than in normal wild type mice, but it was significantly lower in imidapril treated and elastaseapplied wildtype mice than in elastaseapplied wildtype mice (Fig. 6A ). Significant attenuation of the MMP9 activity compared with elastaseapplied wildtype mice was observed in elastase applied AT 1 receptor-knockout mice (Fig. 6A) . Further more, the MMP9 activity was significantly lower in imidapriltreated and elastaseapplied AT 1 receptorknockout mice than in elastaseapplied AT 1 receptorknockout mice (Fig. 6A) .
ACE activity in the aorta was significantly augmented in elastaseapplied wildtype mice compared with normal wildtype mice (Fig. 6B) . ACE activity, unlike MMP9 activity, was not different between elastaseapplied Fig. 5 . Effects of imidapril on luminal area in aorta and elastic degradation score after elastase application in wildtype and AT1 receptor-knockout mice. Typical aorta slices and typical elastic fibers (left upper) from a normal wildtype mouse, an elastase applied wildtype mouse, an imidapriltreated and elastaseapplied mouse, a normal AT1 receptor-knockout mouse, an elastase applied AT1 receptor-knockout mouse, and an imidapriltreated and elastaseapplied AT1 receptor-knockout mouse stained with Elastica van Gieson stain (A). Scale bars show 0.5 mm. The luminal area (B) and the elastic degradation score (C) in the aorta in normal wildtype mice (N: Wildtype, n = 7), elastaseapplied wildtype mice (E: Wildtype, n = 7), imidapriltreated and elastase applied wildtype mice (E + I: Wildtype, n = 7), normal AT1 receptor-knockout mice (N: AT1KO, n = 7), elastaseapplied AT1 receptor-knockout mice (E: AT1KO, n = 7), and imidapriltreated and elastaseapplied AT1 receptor-knockout mice (E + I: AT1KO, n = 7). **P < 0.01 vs. elastaseapplied wildtype mice. # P < 0.05 and ## P < 0.01 vs. elastaseapplied AT1 receptorknockout mice.
wildtype and AT 1 receptor-knockout mice (Fig. 6B) . The ACE activity was significantly lower in imidapril treated and elastaseapplied AT 1 receptor-knockout mice than in elastaseapplied AT 1 receptor-knockout mice (Fig. 6B ).
Discussion
The interaction between ACE inhibitors and the human MMP9 active domain has been studied, and binding diversity in the interaction structure of especially lisinopril and imidaprilat has been found (11 -13, 20) . In this study, diversity was also found in the structure of mouse MMP9 because of the high homologous structure of the active site compared with human MMP9. The difference in inhibitory activity of ACE inhibitors by the activation methods seems to be caused by this binding diversity, and similar diversity may come up in the case of other MMP9 inhibitors (25, 29, 30) . Further more, the template MMP9 structure in this study included fibronectin domains. In our previous studies, the template was only the active domain (PDB code: 1GKC) where Gly 215 and Gln 391 were connected in order to omit the fibronectin part (28) . This modification was placed near the Cterminal substrate binding site including the S1' site and might affect the binding of inhibitors to the Cterminal site. However, the directions of the imidazolidine ring of imidaprilat in the MMP9 complex were different between the previous study (human MMP9) and the present study (mouse MMP9), so that this difference might be caused by the difference in the template structures rather than the species.
In the present study, the elastaseinduced AAA model in mice was used for evaluation of imidapril. Elastase induced AAA has been widely known, and this method involves elastase application to the aorta. The mechanism of AAA development is based on the disrupted nature of elastin, which plays a crucial role in the maintenance of the structural integrity of the artery, just after elastase application. However, porcine pancreatic elastase was not detectable in aortic wall extracts within 24 h of elastase perfusion, indicating that proteinases other than pancreatic elastase are responsible for the late degrada tion of aortic wall elastin associated with aneurysmal dilatation (31) . On the other hand, the gradual expansion of the aorta after elastase application was accompanied by a significant augmentation of MMP9 activity via accumulation of inflammatory cells in the aorta (31) . In MMP9-knockout mice, aortic elastin degradation was significantly attenuated in a CaCl 2 induced AAA mouse model (32) . In the present study, in all groups that showed suppressed MMP9 activity, the elastic degrada tion score was significantly attenuated compared with elastaseapplied wildtype mice, and the greatest attenuating effect on MMP9 activity and on the elastic degradation score was accompanied by imidapriltreated and elastaseapplied AT 1 receptor-knockout mice. These findings show the involvement of MMP9 augmentation in the progression of AAA after the elastase treatment.
In elastaseapplied aorta in rats, both ACE gene expression and protein levels were augmented along with the expansion of the aorta after elastase application (33) . Angiotensin II is known to induce MMP9 gene expres sion via augmentation of ROS, and the augmentation of MMP9 may play a critical role in the pathogenesis of AAA induced by elastase in mice (7, 8, 31, 34) . In fact, an MMP inhibitor prevented AAA progression after elastase application, and an ACE inhibitor also prevented AAA progression, along with attenuation of MMP9 activity (8, 35) . In patients with AAA, augmen tations of ACE and MMP9 activities have been observed (6, 36) . These observations may indicate that augmenta tion of angiotensin II formation is involved in AAA progression via MMP9 induction. In the present study, both ACE and MMP9 activities were significantly augmented after elastase application in wildtype mice; , elastaseapplied wildtype mice (E: Wildtype, n = 7), imidapriltreated and elastaseapplied wildtype mice (E + I: Wildtype, n = 7), normal AT1 receptor-knockout mice (N: AT1 KO, n = 7), elastaseapplied AT1 receptor-knockout mice (E: AT1KO, n = 7) and imidapriltreated and elastaseapplied AT1 receptor-knockout mice (E + I: AT1KO, n = 7). **P < 0.01 vs. elastaseapplied wild type mice. ## P < 0.01 vs. elastaseapplied AT1 receptorknockout mice.
however, we were unable to show the localizations of ACE and MMP9 in the aorta from the elastaseinduced mice by immunohistological staining. Therefore, the direct interaction between ACE and MMP9 remains unclear, but the augmentation of ACEdependent angio tensin II formation after elastase application might be involved in the AAA progression via MMP9 augmenta tion in wildtype mice.
AT 1 receptor-knockout mice were used in the present study, and this model that has no target for angiotensin II action resulted in downregulating angiotensin II action. For example, although angiotensin II maintains homeo stasis of blood pressure, the blood pressure was signifi cantly lower in AT 1 receptor-knockout mice than in wildtype mice. The aortic expansion just after elastase application was not different between wildtype and AT 1 receptor-knockout mice. This finding suggested that the direct elastaseexpanding effect of aorta was unrelated to angiotensin II action. On the other hand, the progression of AAA from just after to 14 days after elastase application might be related to angiotensin II action, because the aortic expansion after elastase appli cation was significantly attenuated in AT 1 receptorknockout mice compared with that in wildtype mice. ACE activity was significantly augmented in the elastase induced AAA in AT 1 receptor-knockout mice, as ob served in wildtype mice. However, the aortic expansion was partially, but significantly, attenuated in AT 1 recep tor-knockout mice compared with wildtype mice after elastase application. Although angiotensin II formation might be increased by augmentation of ACE in the aorta, the target of angiotensin II, the AT 1 receptor, was not present, which resulted in attenuating angiotensin II action. In fact, ACE activity in the aorta was not signifi cantly different between wildtype and AT 1 receptorknockout mice, but the MMP9 activity that is induced by angiotensin II was significantly attenuated in AT 1 receptor-knockout mice. This attenuation of MMP9 activity in AT 1 receptor-knockout mice may be included in the mechanism that prevents AAA progression. However, the blood pressure was significantly lowered in AT 1 receptor-knockout mice, and the preventive effect of aortic expansion might also be included in the hypotensive effect, in addition to downregulation of angiotensin II action.
Habashi et al. (37) demonstrated the important role of angiotensin II type 2 (AT 2 ) receptors in the development of AAA using AT 2 receptor-knockout mice. In that study, the aortic diameter was larger in AAA develop ment in AT 2 receptor-knockout mice than in normal mice, suggesting that the angiotensin II action through AT 2 receptors attenuates AAA progression. They showed that the action of angiotensin II through AT 2 receptors antagonized transforming growth factor b-mediated extracellular signalregulated kinase, and this action contributed to the attenuation of AAA development in mice. In the present study, the ratios of the AT 2 receptor mRNA level to the GAPDH mRNA level were 0.22 ± 0.01 and 0.49 ± 0.03 before and after elastase application in wildtype mice (n = 4), respectively, and 0.36 ± 0.02 and 1.22 ± 0.12 before and after elastase application in AT 1 receptor-knockout mice (n = 4), respectively. Both ratios before and after elastase application were significantly higher in AT 1 receptorknockout mice than in wildtype mice. On the other hand, ACE activity was significantly reduced by imi dapril treatment in wildtype and AT 1 receptor-knockout mice compared with wildtype and AT 1 receptorknockout mice, respectively. We did not measure the angiotensin II level in aortas. However, ACE activity was reduced by imidapril treatment, and angiotensin II levels might be lowered by ACE inhibition in the aorta (38) . Therefore, the action of angiotensin II through AT 2 receptors may be weakened by imidapril treatment, but the action might be slightly involved in the attenuat ing mechanism of AAA progression by imidapril.
Imidapril did not show a further hypotensive effect in AT 1 receptor-knockout mice, although it showed a significant hypotensive effect in wildtype mice. On the other hand, significant attenuations of ACE activity in the aorta were observed both in imidapriltreated wildtype and AT 1 receptor-knockout mice. This finding clearly showed that the dose of imidapril used in the present study adequately inhibited aortic ACE activity in vivo, but the inhibition of angiotensin II formation by imidapril could not contribute to lowering the blood pressure in AT 1 receptor-knockout mice. Previously, Yoshiyama et al. (39) demonstrated that 10 mg/kg of imidapril attenuated the cardiac dysfunction without hypotension in AT 1 receptor-knockout mice, although the mechanism was unclear. In the present study, at least this mechanism of imidapril for preventing AAA progression did not include a hypotensive effect. Although angiotensin II induces MMP9 expression, factors other than angiotensin II stimulation also con tribute to the augmentation of MMP9 (9) . An active form of imidapril, imidaprilat, directly inhibited MMP9 activity in aortic extract. Therefore, the mechanism of imidapril for attenuation of AAA progression may involve attenuating MMP9 activity via mechanisms other than the inhibition of ACE, such as direct inhibition of MMP9.
We did not measure other proteases that may be related to the development of AAA. For example, cysteine proteases such as cathepsin S and MMP2 have been shown to be related to AAA progression (40, 41) . ACE inhibitors do not affect cysteine protease activities, but they could directly inhibit MMP2 activity (10, 42, 43) . In mice, MMP2 activity was augmented after elastase application (31) . However, AAA was significantly pre vented in MMP9-knockout mice, although augmenta tion of MMP2 activity after elastase application was not affected (31) . On the other hand, both MMP2 and MMP9 activities were augmented in CaCl 2 induced AAA mice, and a reduction in MMP2 activity, but not MMP9 activity, resulted in attenuation of AAA development (41) . The effect of imidapril against aortic MMP2 activity after elastase application was not examined in the present study, and further study is needed to determine whether imidapril affects AAA related proteases other than MMP9.
In patents with AAA, Hackam et al. (44) reported the utility of ACE inhibition to decrease AAA progression, but in contrast, Sweeting et al. (45) reported that ACE inhibitors were associated with an increased AAA growth rate. In experimental models, many agents have shown useful effects for the prevention of AAA progression, but there is no evidence that these agents clearly show usefulness against AAA progression in the clinic. Multiple mechanisms may be related to AAA progres sion in patients, and the mechanisms may differ among patients with AAA. Combination therapy may be needed to attenuate the various factors related to the mechanism of AAA progression in order to prevent AAA progres sion in the clinical setting.
In conclusion, direct MMP9 inhibition by ACE inhibitors, in addition to angiotensin II attenuation, may contribute to attenuate AAA progression.
